Credit: Shutterstock photoThe Relative Strength ( RS ) Rating for PTC Therapeutics ( PTCT ) climbed into a higher percentile Friday, as it got a lift from 66 to 77.
[ibd-display-video id=2368044 width=50 float=left autostart=true] This unique rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 as they begin their biggest climbs. See if PTC Therapeutics can continue to rebound and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
PTC Therapeutics is working on a consolidation with a 22.10 buy point . See if the stock can break out in heavy volume.
Earnings growth increased last quarter from 0% to 20%. But sales fell from 207% to 82%.
PTC Therapeutics holds the No. 103 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Sucampo Pharmaceuticals ( SCMP ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
